The U.S. Chamber submitted comments to the European Commission as it considers revisions and updates to its General Pharmaceuticals Legislation, which is Europe’s attempt to foster innovation, improve the resiliency of the healthcare sector in Europe, bolster supply chain security, and ensure access to innovative medicines across the EU. We encouraged the EU to do a better job of rewarding and prioritizing innovation, guarantee strong IP protections for manufacturers, and preserve open and integrated global supply chains rather than attempting to cut Europe off from the global economy in healthcare. We also focused on the importance of digital health and transatlantic coordination, including for research and pandemic response and recovery.
More from this topic
International
World Bank Aims to Hone Business Environment for the Digital Age
The World Bank is creating a new tool to help policymakers and investors evaluate how successful different governments are in meeting the challenges of recovery and competitiveness.
By Gary Litman
International
US-ASEAN Summit: A Timely Opportunity with A Vital Region
By John Goyer
International
Workers at Panasonic Facility in Mexico Elect New Union
By Stephanie Ferguson
International
South Korea Considers Additional Network Fees for Foreign Content Providers, Raising Concerns under KORUS
By Sean Heather
International
Why Rule of Law Should Act as the Foundation for Market Competition
By Megan Bridges